{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Annovis Bio, Inc. technically bullish or bearish?
As of May 7, 2025, the market trend is mildly bearish, influenced by daily moving averages and weekly Dow Theory, though mixed signals from the MACD, Bollinger Bands, RSI, and OBV suggest caution.
Who are in the management team of Annovis Bio, Inc.?
As of March 2022, the management team of Annovis Bio, Inc. includes Chairman Mr. Michael Hoffman and Executive Board Member Dr. Maria Maccecchini, along with Board Members Dr. Claudine Bruck, Mr. Robert Whelan, and Mr. Mark White.
What does Annovis Bio, Inc. do?
Annovis Bio, Inc. is a clinical stage pharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. As of March 2025, it has a market cap of $51.25 million and reported a net profit loss of $6 million.
How big is Annovis Bio, Inc.?
As of Jun 18, Annovis Bio, Inc. has a market capitalization of 51.25 million, with net sales of 0.00 million and a net profit of -29.06 million over the latest four quarters. As of Dec'24, shareholder's funds were 9.31 million and total assets were 13.93 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
